Skip to main navigation Skip to search Skip to main content

Ketamine treatment for refractory anxiety: A systematic review

Research output: Contribution to journal › Review article › peer-review

Abstract

There is a growing interest in the psychiatric properties of the dissociative anaesthetic ketamine, as single doses have been shown to have fast-acting mood-enhancing and anxiolytic effects, which persist for up to a week after the main psychoactive symptoms have diminished. Therefore, ketamine poses potential beneficial effects in patients with refractory anxiety disorders, where other conventional anxiolytics have been ineffective. Ketamine is a noncompetitive antagonist of the N-methyl-d-aspartate (NMDA) glutamate receptor, which underlies its induction of pain relief and anaesthesia. However, the role of NMDA receptors in anxiety reduction is still relatively unknown. To fill this paucity in the literature, this systematic review assesses the evidence that ketamine significantly reduces refractory anxiety and discusses to what extent this may be mediated by NMDA receptor antagonism and other receptors. We highlight the temporary nature of the anxiolytic effects and discuss the high discrepancy among the study designs regarding many fundamental factors such as administration routes, complementary treatments and other treatments.

Original languageEnglish (US)
Pages (from-to)4412-4426
Number of pages15
JournalBritish Journal of Clinical Pharmacology
Volume88
Issue number10
DOIs
StatePublished - Oct 2022
Externally publishedYes

Keywords

  • anxiety
  • anxiolytic
  • depression
  • ketamine
  • ketamine infusion
  • refractory anxiety
  • treatment-resistant depression

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Ketamine treatment for refractory anxiety: A systematic review'. Together they form a unique fingerprint.

Cite this